The FDA has stated explicitly that "retatrutide and cagrilintide cannot be used in compounding under federal law." The reason is that retatrutide does not appear on the 503A bulks list, is not a component of any FDA-approved drug, and does not have an applicable USP or NF monograph
Weeks 2 to 4: First Measurable Shifts Noticeable energy improvement
We are required to inform you that there is no intention, implied or otherwise that represents or infers that these products or statements be used in the cure, diagnosis, mitigation, treatment, or prevention of any disease
Increases Energy Expenditure via Glucagon Receptor Activation A defining benefit of Retatrutide is its activation of the glucagon receptor, which is associated with increased energy expenditure and thermogenic activity
A: Definitely
Although not yet approved for type 1 diabetes, GLP-1 agonists have been tested in multiple trials involving people with the condition